Skip to main content
- Funds
- Insights
- Capabilities
- About Us
- My Account
Our Funds
Fund Documents
Global Multi-Strategy Fund
We offer forums, educational programs, and targeted thought leadership for clients seeking to grow their knowledge of equity and fixed income markets, derivatives, asset allocation strategies, and risk-management practices.
How to reposition equity portfolios for recurring AI disruption
With a growing range of industries hit by sell-offs, Multi-Asset Strategist Nanette Abuhoff Jacobson explores how to reposition equity portfolios for recurring AI disruption.
Chart in focus: Rethinking the bond mix
Alex King and Josh Riefler explore the evolving role of global government bonds in portfolios against a backdrop of tight spreads.
2026 Private Credit Roundtable
In this three-part video series, our private credit experts explore the evolving role of banks, where we are in the credit cycle, and potential AI/data center opportunities in private credit.
Private Market Perspectives 2025: Full Picture
At our Annual Meeting, we explored private markets trends, from private credit growth to opportunities across the credit continuum, powered by our integrated public and private insight.
Monthly Market Review — January 2026
A monthly update on equity, fixed income, currency, and commodity markets.
Secondary investment: Flexibility in private equity
Our private equity experts highlight how secondary transactions offer liquidity solutions for LPs, capital support for GPs, and a growing opportunity set.
European equities: time to reassess?
Many investors remain cautious on European equities, but Multi-Asset Portfolio Manager Supriya Menon and Lead Researcher Patrick Wattiau argue it is time to consider what could go right for European equities.
Don’t stop believin’ in emerging market equities
Multi-Asset Strategist Nanette Abuhoff Jacobson explains why emerging market equities have become her highest-conviction view across asset classes.
Another banner year for emerging markets local debt in 2026?
Our experts highlight EM local debt's strong 2025 performance and explain their bullish outlook for 2026.
Disquiet in quality: What happened and what now?
Quality has been lagging since 2021, with underperformance accelerating sharply in 2025. Where does this leave investors now?
China’s biotech surge (and its impact on biotech venture capital)
China’s biotech sector’s long-term potential is underpinned by lower costs, faster development timelines, and increasingly translatable clinical data. In our new paper, we explore the implications for US and European biotechs.
URL References
Related Insights